Alamar Biosciences (NASDAQ:ALMR) Announces Earnings Results

Alamar Biosciences (NASDAQ:ALMR) posted its quarterly earnings results on Tuesday. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.14, Zacks reports. The business had revenue of $29.43 million for the quarter.

Alamar Biosciences Trading Up 30.7%

Shares of NASDAQ ALMR opened at $36.57 on Wednesday. The business has a fifty day moving average price of $24.90. Alamar Biosciences has a 52 week low of $18.84 and a 52 week high of $38.54. The stock has a market capitalization of $2.53 billion and a P/E ratio of -21.02.

Alamar Biosciences News Roundup

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Q2 earnings beat expectations: Alamar reported adjusted earnings of $(0.22) per share, ahead of the $(0.36) consensus estimate, while revenue reached $29.43 million. The company’s quarterly revenue growth was reported at 82%, supporting the bullish reaction. Alamar Biosciences Q2 earnings report
• Positive Sentiment: 2026 revenue outlook raised or reaffirmed above expectations: Management forecast full-year revenue of $116 million to $120 million, exceeding the roughly $113.1 million analyst consensus. The company is targeting more than 100 instruments and at least $400,000 in pull-through revenue per instrument, signaling confidence in demand and adoption. Alamar 2026 revenue outlook
• Positive Sentiment: Strategic partnership expanded: Alamar expanded its global collaboration with the Alzheimer’s Disease Data Initiative and Gates Ventures. The relationship could strengthen the company’s visibility and support future use of its proteomics platform in Alzheimer’s research. Alamar partnership expansion
• Neutral Sentiment: JPMorgan raised its price target: JPMorgan increased its target from $32 to $35 and maintained an “overweight” rating. The favorable rating is supportive, although the new target remains below the reported market price, suggesting limited near-term upside at that valuation. JPMorgan Alamar price target update
• Neutral Sentiment: Short-interest data provided no meaningful signal: Reported short interest was zero shares with a zero-day days-to-cover ratio, so the data does not indicate notable short-covering activity behind the increase.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a research note on Saturday, April 25th. Zacks Research raised Alamar Biosciences to a “hold” rating in a research note on Wednesday, May 13th. TD Cowen reiterated a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Leerink Partners assumed coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Bank of America initiated coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 target price for the company. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.80.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.